Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial.
Fiche du document
- doi: 10.1016/j.eclinm.2021.101188
- issn: 2589-5370
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.eclinm.2021.101188
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34778734
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2589-5370
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_D190F50E05B14
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Days of the weekCiter ce document
N.D. Labhardt et al., « Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. », Serveur académique Lausannois, ID : 10.1016/j.eclinm.2021.101188
Métriques
Partage / Export
Résumé
Since the beginning of the COVID-19 pandemic, no direct antiviral treatment is effective as post-exposure prophylaxis (PEP). Lopinavir/ritonavir (LPV/r) was repurposed as a potential PEP agent against COVID-19. We conducted a pragmatic open-label, parallel, cluster-randomised superiority trial in four sites in Switzerland and Brazil between March 2020 to March 2021. Clusters were randomised to receive LPV/r PEP (400/100 mg) twice daily for 5 days or no PEP (surveillance). Exposure to SARS-CoV-2 was defined as a close contact of >15 minutes in
